Free Trial
NASDAQ:IRD

Opus Genetics 11/12/2024 Earnings Report

Opus Genetics logo
$0.95 +0.02 (+1.75%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$0.96 +0.01 (+0.59%)
As of 05/2/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Opus Genetics EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Opus Genetics Revenue Results

Actual Revenue
$3.87 million
Expected Revenue
$1.17 million
Beat/Miss
Beat by +$2.70 million
YoY Revenue Growth
N/A

Opus Genetics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Opus Genetics' next earnings date is estimated for Friday, May 9, 2025, based on past reporting schedules.

Conference Call Resources

Opus Genetics Earnings Headlines

What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.
Craig-Hallum bullish on Opus Genetics, initiates with a Buy
Opus Genetics initiated with a Buy at Craig-Hallum
See More Opus Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email.

About Opus Genetics

Opus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

View Opus Genetics Profile

More Earnings Resources from MarketBeat